Akshi Srivastava completed her Bachelor of Technology in Biotechnology at Guru Gobind Singh Indraprastha University, Delhi, India, in 2021. Her undergraduate thesis focused on an in silico approach to the identification of BACE1 inhibitors for Alzheimer’s disease, employing computational methods for protein modelling, docking, and target validation.
She subsequently pursued a Master’s degree with a specialization in Immunobiology at the University of Vienna, Austria, graduating in 2025. During her graduate studies, she developed a strong focus on cancer biology and translational research. Her master’s thesis investigated the therapeutic potential of Lurbinectedin in PARP inhibitor-resistant high-grade serous ovarian carcinoma (HGSOC), utilizing patient-derived cell lines and three-dimensional organoid models to evaluate treatment responses.
In 2023–2024, she completed a research internship at the University of Natural Resources and Life Sciences, Vienna (BOKU), where she contributed to laboratory operations and experimental reproducibility. Her work included protein purification using high-performance liquid chromatography (HPLC) and size-exclusion chromatography, alongside exposure to immunoassay-based analytical techniques.
From April 2024 to March 2025, she was employed as a Junior Researcher at the Medical University of Vienna, Department of Obstetrics and Gynaecology. In this role, she worked extensively with patient-derived ovarian cancer models, including both 2D cell cultures and 3D organoid systems. Her research involved molecular and cellular techniques such as RT-qPCR, immunohistochemistry, nucleic acid extraction, and viability and cytotoxicity assays, as well as live-cell imaging–based drug screening, contributing to the investigation of therapeutic responses in preclinical cancer models.
Since 2025, she has been working as a Research Assistant at the Institute of Cell and Tissue Culture Technologies (ICTCT) at BOKU, where she continues to contribute to research in cell-based systems and biotechnological applications.
Her research interests lie at the intersection of oncology, immunobiology, and translational medicine, with particular emphasis on patient-derived model systems and therapeutic response evaluation.
